Aziyo gains on data for wound healing product in cardiac implantation
JuSun
Aziyo Biologics (NASDAQ:AZYO) added ~8% pre-market Friday after announcing study data supporting the potential of its healing product CanGaroo Biologics Envelope when with a cardiac implantable electronic device (CIED).
The U.S.-based trial involved 43 patients who underwent CIED implantation with either CanGaroo Envelope, Medtronic’s (MDT) Tyrx non-biologic envelope, or no envelope (CanGaroo, n=11, Tyrx, n=15, or no envelope, n=17).
At least four months after the initial placement, the patients were subject to an evaluation when they returned for a revision procedure.
Highlights of the interim data indicated that CanGaroo reoperations outperformed in easier lead mobilization, easier generator mobilization, and less overall procedural difficulty. Those on CanGaroo also showed 83% fewer capsulectomy procedures compared to the Tyrx group (p=0.04).
“This study demonstrates that biologic envelopes, such as CanGaroo, can improve patient care and decrease complications following device implantation,” John Catanzaro, the lead investigator and an Associate Professor of Medicine at the University of Florida, remarked.
The data will be presented at the Heart Rhythm Society on Sunday at the Morial Convention Center in New Orleans, LA.